// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

The association of age of puberty onset and adulthood lung function is mediated by height growth rate in adolescence and its induced DNA methylation in young adulthood

Li L - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Successful rapid push subcutaneous desensitization in a patient with delayed local hypersensitivity reactions to immunoglobulins

Ghurye RR - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Prednisolone

Dextromethorphan allergy

Elkhalifa S - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anaphylaxis

Dextromethorphan

Efficacy and safety outcomes for switching to lanadelumab from prior LTP: Findings from an interim analysis of the HELP OLE study

Magerl M - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

DX2930

Regional audit of paediatric anaphylaxis management in the midlands: Are we following national guidance?

Dhesi A - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anaphylaxis

N/A

Transition of children with significant allergies and complex special needs‐ our experience

Kaniti A - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Anaphylaxis

N/A

The prevalence of systemic reactions and their sensitization profiles in children with pollen food syndrome

Umanets T - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Allergic rhinitis

PR-10

The effect of probiotic supplementation on the acquisition of tolerance to cows’ milk protein allergy

Kaminskaite V - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A case of systemic allergy to quorn

Tadros S - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Dyspnea

Epinephrine

Mushroom allergy: A case series

Kayode OS - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Tuberculosis

N/A

Allergy to chicken meat and chicken meat‐dependent exercise‐induced anaphylaxis: Case series

Harper V - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anaphylaxis

N/A

Investigate the impact of cat allergen from different cat breeds on cat sensitized subject using novel progenitor cell derived basophil activation test

Wu J - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Analysis of dust mite allergen components in asthmatic children from Costa Rica and Ecuador: Focus on Der P 23

Keshavarz B - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

House dust mite priming enhances rhinovirus‐induced inflammasome activation in asthma

Radzikowska U - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Dietary nitrate supplementation increases fractional exhaled nitric oxide: Implications for the assessment of airway health in athletes

Allen H - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Nitric oxide

Effects of long‐term prophylaxis with subcutaneous C1 inhibitor in special patient populations: Findings from the COMPACT open‐label extension trial

Levy DS - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Final results from the ZENITH‐1 study: Oral administration of plasma kallikrein inhibitor BCX7353 for the treatment of attacks in patients with hereditary angioedema

Longhurst HJ - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hereditary angioedema

BCX7353

Effects of subcutaneous C1‐esterase inhibitor on coagulation and fibrinolysis in patients with hereditary angioedema: Findings from the COMPACT And OLE study

Reshef A - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hereditary angioedema

Fibrinogen (IV)

The cambridge peanut allergy clinic: Real world safety and efficacy outcomes during oral immunotherapy with characterised peanut flour

Clark A - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Epinephrine

ARTEMIS: A European, phase 3, randomised, double‐blind, placebo‐controlled trial of AR101 in peanut‐allergic children and adolescents aged 4‐17

Fernndez-Rivas MM - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anaphylaxis

N/A

Copyright © 2026. QuantiNova All rights reserved